Adaptive radiation therapy for cervical cancer using MRI technology
MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos
This study is testing a new way to use MRI technology for radiation therapy in cervical cancer patients to see if it can make treatment safer and more effective.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Institut Sainte Catherine Academic / other |
| Drugs / interventions | Radiation |
| Locations | 1 site (Avignon) |
| Trial ID | NCT05909111 on ClinicalTrials.gov |
What this trial studies
This study explores the feasibility of using a magnetic resonance imaging (MRI)-only approach for adaptive external beam radiation therapy (EBRT) in patients with cervical cancer. By implementing the Varian Ethos therapy system, the study aims to streamline the treatment workflow and reduce the radiation dose to surrounding organs at risk by adapting the treatment to the patient's daily anatomy. The focus is on patients requiring curative treatment for specific stages of cervical cancer, utilizing MRI for precise treatment planning.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with histologically confirmed cervical cancer at specific stages who are eligible for curative radiation therapy.
Not a fit: Patients with metastatic disease or those who have contraindications to MRI examinations will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer radiation therapy for cervical cancer patients.
How similar studies have performed: While the use of adaptive radiation therapy is gaining traction, this specific MRI-only approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years old * Histologically proven cervical cancer (SCC, ADK ou adenous-SCC) * Patient for curative RTCT treatment * FIGO/TNM Stage IB2, IIA, IIB, IIIA, IIIB with or without lymph nodes involvement * WHO \< 2 * No pregnancy * Informed consent dated and signed * Patient affiliated or beneficiary of a social security scheme * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). Exclusion Criteria: * Metastatic disease * Contraindications to IRM examinations (claustrophobia, presence of metallic elements..) * Signes of active infection or serious health problems * Historic of abdominal or pelvis RT * Surgical history: partial or total hysterectomy
Where this trial is running
Avignon
- Institut Sainte Catherine — Avignon, France (Recruiting)
Study contacts
- Study coordinator: Catherine Khamphan, PhD
- Email: c.khamphan@isc84.org
- Phone: 0490276543
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.